The global blood screening market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7%.
The global market is broadly classified into technology, product & service, end user, and region.
On the basis of technology, the market is segmented into NAT, ELISA, rapid tests, western blot assays, and NGS. The NAT segment is further subsegmented into transcription-mediated amplification (TMA) and real-time PCR. The ELISA segment is further classified based on various platforms and generations.
Download FREE Brochure @https://www.marketsandmarkets.com/pdfdownload.asp?id=267747042
On the basis of platform, the ELISA market is segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). On the basis of generation, the ELISA market is segmented into first generation ELISA, second generation ELISA, third generation ELISA, and fourth & above generation ELISA.
On the basis of product and service, the blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment is further subsegmented into NAT reagents and kits, ELISA reagents and kits, and other reagents and kits. On the basis of purchase mode, the instruments market is segmented into rental purchase and outright purchase.
Based on end user, the blood screening market is segmented into blood banks and hospitals.
Based on region, the market is segmented into North America, Europe, Asia, and RoW.
Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalyst.asp?id=267747042
The major players in the blood screening market are Grifols (Spain), Bio-Rad Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Abbott Laboratories (U.S.), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), and Becton, Dickinson and Company (U.S).
No comments:
Post a Comment